$0.69
1.43% today
Nasdaq, Apr 02, 08:53 pm CET
ISIN
US70387R1068
Symbol
PAVM

PAVmed, Inc. Stock price

$0.70
+0.01 1.30% 1M
-0.63 47.37% 6M
+0.07 11.55% YTD
-1.34 65.69% 1Y
-16.62 95.96% 3Y
-23.99 97.17% 5Y
-167.37 99.58% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.02 2.97%
ISIN
US70387R1068
Symbol
PAVM
Sector

Key metrics

Market capitalization $11.75m
Enterprise Value $41.20m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 13.73
P/S ratio (TTM) P/S ratio 3.92
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 22.15%
Revenue (TTM) Revenue $3.00m
EBIT (operating result TTM) EBIT $-44.49m
Free Cash Flow (TTM) Free Cash Flow $-33.61m
Cash position $1.19m
EPS (TTM) EPS $-2.25
P/E forward negative
P/S forward 57.32
EV/Sales forward 200.98
Short interest 2.11%
Show more

Is PAVmed, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

PAVmed, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast PAVmed, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast PAVmed, Inc.:

Buy
100%

Financial data from PAVmed, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
3 3
22% 22%
100%
- Direct Costs 6.04 6.04
35% 35%
201%
-3.04 -3.04
56% 56%
-101%
- Selling and Administrative Expenses 34 34
22% 22%
1,144%
- Research and Development Expense 5.93 5.93
60% 60%
198%
-43 -43
34% 34%
-1,443%
- Depreciation and Amortization 1.20 1.20
62% 62%
40%
EBIT (Operating Income) EBIT -44 -44
35% 35%
-1,483%
Net Profit 40 40
162% 162%
1,326%

In millions USD.

Don't miss a Thing! We will send you all news about PAVmed, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PAVmed, Inc. Stock News

Neutral
PRNewsWire
6 days ago
Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference NEW YORK , March 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced a campaign, entitled...
Neutral
Seeking Alpha
8 days ago
PAVmed Inc. (NASDAQ:PAVM ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Jeremy Pearlman - Maxim Group Matthew Park - Cantor Fitzgerald Ed Woo - Ascendiant Capital Operator Good morning, and welcome to PAVmed's Fourth Quarter 2024 Business Update...
Neutral
PRNewsWire
8 days ago
Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies  Veris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch  PAVmed completed debt restructuring and Lucid deconsolidation to regain Nasdaq compliance and strengthen balan...
More PAVmed, Inc. News

Company Profile

PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The firm conducts its operations in four divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy and Emerging Innovations. The GI Health division consists of Edouard Esophageal DNA Test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus Technology. The Minimally Invasive Interventions division consists of CarpX, which is a patented, single-use disposable, minimally invasive device designed to treat carpal tunnel syndrome. The Infusion Therapy division consists of PortIO, which is a novel, patented, implantable, intraosseous vascular medical device; and NextFlo, which is designed to deliver gravity-driven infusions independent of the height of the IV bag. The Emerging Innovations division refers to a diversified and expanding portfolio of innovative products designed to address unmet clinical needs across a broad range of clinical conditions. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Head office United States
CEO Lishan Aklog
Employees 39
Founded 2014
Website www.pavmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today